Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris healthcare sa-nv - phenprocoumon 3 mg - tablet - 3 mg - phenprocoumon 3 mg - phenprocoumon

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (germany) - phenprocoumon - oral tablet - 3mg

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

denk pharma gmbh & co. kg - torasemide - tablets - 5mg

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

denk pharma gmbh & co. kg - torasemide - tablets - 10mg

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

acino pharma ag - clopidogrel (clopidogrel besilate) - tablets film-coated - 75mg

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

acino pharma ag - clopidogrel (clopidogrel besilate) - tablets film-coated - 75mg

Singapur - angličtina - HSA (Health Sciences Authority)

roche singapore pte. ltd. - phytomenadione - injection - 10 mg/ml - phytomenadione 10 mg/ml

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - methotrexate sodium, quantity: 2.742 mg (equivalent: methotrexate, qty 2.5 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate - antineoplastic chemotherapy treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. chexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy (see warnings box and section 4.4) because of the high risk attending to its use, chexate is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and / or after dermatologic consultations. rheumatoid arthritis chemotherapy (see warnings box and section 4.4) management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to or intolerant of an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored (see section 4.4, and 4.5). steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - methotrexate sodium, quantity: 10.97 mg (equivalent: methotrexate, qty 10 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose - antineoplastic chemotherapy treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. chexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy (see warnings box and section 4.4) because of the high risk attending to its use, chexate is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and / or after dermatologic consultations. rheumatoid arthritis chemotherapy (see warnings box and section 4.4) management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to or intolerant of an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored (see section 4.4, and 4.5). steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - imatinib mesilate, quantity: 478 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - imatinib rbx is indicated for the: ? treatment of patients with chronic myeloid leukaemia (cml) ? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy ? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials) ? treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).